Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: A phase II Southwest Oncology Group study (S0339)

PURPOSE: Bortezomib is a small-molecule proteasome inhibitor with single-agent activity in patients with non-small cell lung carcinoma (NSCLC) and synergy with gemcitabine in preclinical studies. This phase II study of bortezomib in combination with gemcitabine/carboplatin was conducted in chemother...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Davies, Angela M., Chansky, Kari, Lara, Primo N., Gumerlock, Paul H., Crowley, John, Albain, Kathy S., Vogel, Stanley J., Gandara, David R.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2009
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3024911/
https://ncbi.nlm.nih.gov/pubmed/19096312
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e3181915052
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky